Idera to Host Conference Call and Webcast to Report Fourth Quarter and Full Year 2013 Financial Results on Thursday, March 13, 2014
In order to participate in the conference call, please dial 1-866-271-6130 (domestic) or 1-617-213-8894 (international) and provide the access code 13838305. The live webcast can be accessed under “Investor Events” in the Investors section of the Company’s website at www.iderapharma.com or you may use the link http://edge.media-server.com/m/p/tni65ic2/lan/en .
A replay of the call will be available at
About
Idera’s proprietary technology involves creating novel nucleic acid therapeutics designed to inhibit over-activation of Toll-like Receptors (TLRs). Idera is developing these therapeutics for the treatment of genetically defined forms of B-cell lymphoma and for autoimmune diseases with orphan indications. In addition to its TLR programs, Idera is developing gene silencing oligonucleotides that it has created using its proprietary technology, to inhibit the production of disease-associated proteins by targeting RNA.
Source:
Investor Contact:
Stern Investor Relations, Inc.
Sarah
McCabe, 267-909-9237
sarah@sternir.com